Bayer stock holds near EUR 49 after Kerendia data

Bayer stock is holding near EUR 49 as August 30, 2026 clinical data on Kerendia and REVEAL keeps pharma momentum in view.

Bayer AG (ISIN DE000BAY0017) shares were quoted at EUR 48.67 on Xetra on August 28, 2026, with a year-to-date gain above 31 percent and a one-week move of 0.39 percent. Recent company news on August 30, 2026 added fresh detail on Kerendia and on the Phase III REVEAL study, giving investors two dated catalysts to track.

Kerendia adds another data point

One report said Kerendia generated EUR 603 million in first-half 2026 sales, up 75 percent from the prior year, while another cited a second-quarter 2026 Kerendia revenue of EUR 329 million, up 80 percent year over year. That combination keeps the drug at the center of Bayer's pharma narrative as the company continues to lean on cardio-renal growth.

The REVEAL update was presented on August 30, 2026 and said the Phase III study met its primary endpoints for sensitivity and specificity in cardiac amyloidosis. The same release said 170 patients were treated, 55 experienced at least one treatment-emergent adverse event, and only one event was considered related to the radiotracer.

What the market is pricing

At EUR 48.67, Bayer's shares remain below the EUR 50 level that has framed recent trading, while a later quote in the same coverage put the stock at EUR 48.76 on August 29, 2026. A published average price target of EUR 57.39 would imply 17.91 percent upside from the August 28 close, although the share price already reflects a strong move this year.

For investors, the key point is that the stock is not moving on a single headline but on a cluster of dated medical and commercial figures. That matters more than the tone of the news flow itself.

Kerendia in practice

Kerendia is Bayer's kidney and heart medicine built around finerenone, and the latest sales figures show why it matters to the group. First-half 2026 revenue of EUR 603 million and second-quarter revenue of EUR 329 million point to continued demand in the cardio-renal franchise.

Shares and valuation

Bayer stock traded at EUR 48.67 on August 28, 2026, with the same coverage citing EUR 48.76 in a Tradegate quote on August 29, 2026. The shares are also being measured against an average target of EUR 57.39, which leaves room for further re-rating if the current earnings and pipeline backdrop holds.

More on Bayer AG

Company: Bayer AG
ISIN: DE000BAY0017
Ticker: BAYN
Exchange: Xetra
Price (as of August 28, 2026): EUR 48.67
Market cap: EUR 43.53 billion
Sector / Industry: Health Care / Pharmaceuticals
Index membership: DAX 40